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Letters to the Editorindicates lactate acidosis, will affect
the blood lactate concentration, espe-
cially in very little infants.2 This study
has not analyzed the use of banked
blood in 2 groups statistically. There-
fore, is it more appropriate to limit
the inclusion objects to a more narrow
age span?
Second, crystal solutions would be
used in the extracorporeal circulation.
The crystal solutions in use now in-
clude Ringer’s lactate and Ringer’s ac-
etate. Lactate has 2 isoforms: L-lactate
and D-lactate. L-lactate is the products
of anaerobic glycolysis in humans and
has been used as a marker of cellular
hypoxia and tissue malperfusion.3 It
would be converted to sodium bicar-
bonate by tricarboxylic acid cycle.
However, D-lactate is mostly exoge-
nous from Ringer’s lactate solution.
Its clearance is much slower than L-
lactate, mainly depending on the liver
function.3 Massive exogenous D-lac-
tate Ringer’s solution infusion would
cause iatrogenic hyperlactacidemia
in those infants with immature liver
function. This phenomenon would
not occur when Ringer’s acetate is
used in CPB. However, this study has
not mentioned the kinds and dosage
of the crystal solution.
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To the Editor:
The editorial by Lapeyre and
colleagues,1 ‘‘Prosthetic heart valves:
Difficult to make something simple,’’
emphasizes the need for more dura-
ble tissue valves for patients younger
than 65 years, especially juveniles
and young adults in emerging coun-
tries. To address that need, our group
has worked on the concept of a non-
immunogenic autologous tissue valve
for the last 25 years. The initial clin-
ical application was a stent-mounted
valve made in the operating room at
the time of valve replacement.2
More recently, a totally stentless
aortic valve made with disposable in-
struments at the time of valve re-
placement has been developed and
used clinically.3 Follow-up of the first
11 patients implanted with the stent-
less autologous pericardial valve in
a prospective pilot study from Febru-
ary 2003 to May 2005 at the Hare-
field Hospital by Dreyfus can be
seen, before publication, on the
webcast of the 2010 American Asso-
ciation for Thoracic Surgery annual
meeting in Toronto.4 The first patient
in the series was a 42-year-old man
with a heavily calcified bicuspid aor-
tic valve, a gradient of 131 mm Hg,
and an ascending aortic aneurysm.
He has normal valve function with
no evidence of calcification 7.2 years
post-aortic valve reconstruction. The
last patient in the series was a 22-
year-old woman with congenital aor-
tic stenosis and a calcified bicuspid
aortic valve with a gradient of 71
mm Hg. She has normal valve func-
tion with no evidence of calcification
5 years after aortic outflow enlarge-
ment and aortic valve reconstruction.
These results suggest that lightly
tanned autologous pericardium may
be a suitable biomaterial for fabricat-
ing a more durable tissue heart valve
for younger patients. The use of
autologous tissue and disposable
instruments for the valve reconstruc-of Thoracic and Cardiovascular Surgetion has the potential for being
a cost-effective solution to the need
for a tissue heart valve in emerging
countries.
It is largely forgotten that the first
tissue heart valves weremade of autol-
ogous tissue, by Ake Senning in the
early 1960s. He did freehand recon-
struction of aortic valves with the
patient’s own fascia lata. Senning ex-
plained presciently why he used autol-
ogous tissue: ‘‘Having worked with
organ transplantation, I felt the allo-
grafts or homografts would be slowly
destroyed by immunologic factors. In
the same year, I began replacing the
aortic valve with autogenous fascia
lata, which was taken sterile at the
time of operation, eliminating the
problems of sterilization, preserva-
tion, immunologic reactions, and
thromboembolism.’’5 He used un-
treated autologous fascia lata, and al-
though 18 of 90 patients survived 12
to 20 years with their reconstructed
aortic valves, 13 with ‘‘no or minimal
dysfunction,’’ most of the valves be-
came insufficient because of thicken-
ing and shrinkage of the tissue.
Others, notably Bj€ork6 and Edwards,7
confirmed poor results with untreated
fascia lata and pericardium, and the
use of autologous tissue fell out of
favor. On revisiting the concept, we
discovered serendipitously that a brief
immersion of autologous pericardium
in dilute buffered glutaraldehyde so-
lution, light tanning,2 eliminated the
thickening and shrinkage that had
been observed by Senning, Bjork,
and Edwards. The tissue had a healthy,
pristine appearance after valve im-
plantation for 5 months in juvenile
sheep, a known severe test for calcific
degeneration. Love8 summarized the
early history of autologous tissue
heart valves in a monograph on the
subject.
The valve industry has shown little
interest in an autologous tissue heart
valve that might prove to be more du-
rable and cost a fraction of currently
available bioprostheses.ry c Volume 141, Number 2 599
FIGURE 1. Preoperative and postoperative computed tomography scans of patients. Defect of
anterior wall of ascending aorta (dotted line); pseudoaneurysm arising from the right anterior wall
of ascending aorta (single arrow); repaired aorta with aortic valvular prosthetic replacement (double
arrow).
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ASCENDING AORTA
COMBINED WITH AORTIC
VALVE INFECTIVE
ENDOCARDITIS AFTER
CARDIAC OPERATIONS FOR
CONGENITALVENTRICULAR
SEPTAL DEFECT
To the Editor:
We read with great interest the arti-
cle of Emaminia and colleagues1 and
congratulate them for their successful
repair of an iatrogenic pseudoaneur-
ysm of the ascending aorta. Their strat-
egy to safely reopen the sternum is to
drain the blood into the oxygenator res-
ervoir for 1 to 2 minutes to have an
empty, relatively collapsed heart and
aortawithout establishment of femoro-
femoral bypass. Wewant to know how600 The Journal of Thoracic and Cmuch blood should be drained and how
to maintain hemodynamics during the
procedures. Fortunately, the pseudoa-
neurysm was located at the back of as-
cending aorta. Otherwise, how would
the hemodynamics problem be dealt
with if the reentry of the sternum was
not uneventful?
Ascending aortic pseudoaneurysms
are found on rare occasions, and direct
surgical repair is the only choice,
but this carries a high risk of fatal
hemorrhage resulting from rupture of
pseudoaneurysm at the time of sternal
reentry. From the limited case reports
in the literature,2-5 the authors
concluded that median sternotomy
with the use of femorofemoral bypass
and hypothermic circulatory arrest is
the strategy of choice.
We recently surgically managed
a case of ascending aortic pseudoa-
neurysm combined with aortic valve
infective endocarditis after congenital
ventricular septal defect. An 11-year-
old boy was admitted to our hospital
2 months later with intermittently
high fever accompanying stridor and
dizziness experienced for approxi-
mately 1 month. Echocardiography
showed masses in the prolapsed right
coronary cusp with severe aortic
regurgitation. Staphylococcus aureus
was cultured from the blood. A
contrast computed tomography scan
showed a defect in the right anteriorardiovascular Surgery c February 2011wall of the ascending aorta 1.5 cm
above the aortic valve, from which
a pseudoaneurysm was arising
(Figure 1). Intravenous antibiotics ac-
cording to in vitro susceptibility test-
ing were continued for 2 more
weeks, bacteremia was controlled,
and operation was performed. The
chest was opened through the previ-
ous scar. After institution of femorofe-
moral bypass, the patient was cooled
to 32C and the heart was relatively
emptied. A sternotomy was then per-
formed. Adhesions over the ascending
aortic pseudoaneurysm and right ven-
tricle were released uneventfully. The
aorta was clamped at 28C and
opened through the pseudoaneurysm,
which was approximately 8 3 7 3
5 cm. The 2.5 3 2.5-cm defect was
at the previous aortotomy site. Cardio-
plegic solution was administered
directly, and the aortic native valve
was replaced by a 21-mm St Jude me-
chanical prosthesis (St Jude Medical
Inc, St Paul, Minn). The aortic defect
was closed using a 5 3 3-cm polyte-
trafluoroethylene patch with 4-0 Pro-
lene suture. The patient was weaned
uneventfully from cardiopulmonary
bypass. The postoperative course was
uncomplicated. No special treatment
was given except for continuing
intravenous antibiotics for another 4
weeks and oral warfarin. The cause
of the pseudoaneurysm appeared to
